Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.

导出 OA

翻译打印收藏纠错

第一作者： Paul V,Viscuse

第一单位： Department of Medicine, University of Virginia, Charlottesville, VA 22903, USA.

作者： Paul V,Viscuse ^[1] ; Rebecca S,Slack-Tidwell ^[2] ; Miao,Zhang ^[3] ; Prih,Rohra ^[3] ; Keyi,Zhu ^[3] ; F Anthony,San Lucas ^[4] ; Eric,Konnick ^[5] ; Patrick G,Pilie ^[6] ; Bilal,Siddiqui ^[6] ; Christopher J,Logothetis ^[6] ; Paul,Corn ^[6] ; Sumit K,Subudhi ^[6] ; Colin C,Pritchard ^[5] ; Rama,Soundararajan ^[7] ; Ana,Aparicio ^[6]

作者单位： Department of Medicine, University of Virginia, Charlottesville, VA 22903, USA. ^[1] Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ^[2] Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ^[3] Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ^[4] Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA. ^[5] Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ^[6] Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ^[7]

关键词 aggressive-variant prostate cancer immunohistochemistry molecular biomarker next-generation sequencing

DOI 10.3390/cancers15245843

PMID 38136389

发布时间 2024-02-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交